Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall tone is neutral to cautiously analytical, with posts referencing demographic factors like age, sex, and BMI affecting weight plateau timelines. Discussions include mention of specific data points—such as activity around the 24–36 week range—and questions about variables influencing outcomes. The tone and word choices suggest a moderate level of curiosity and engagement centered on understanding which factors influence long-term weight stabilization, highlighting both the relevance of the findings and the need for further exploration.
The discussions are mixed; some recognize the study's findings, while others question factors like demographic disparities.
Moderate interest is evident, with some posters engaging actively and others showing minimal curiosity.
Most social discussions are brief, focusing on summarizing findings rather than deep analysis.
The conversations hint at significance for weight management treatments but lack widespread emphasis on clinical implications.
Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials https://t.co/ve62W3z9jm
【備忘】 Clin Obes誌に、RCTデータを用いたセマグルチドによる減量作用持続期間解析。 開始後72週後までは減量が持続。「若年」「女性」では減量持続期間が延長。 https://t.co/sHUmvZ3EFS Jan 12 （ 「この体重でOK」まで下がったらどうすれば？ ）
متى يوصل الجسم لثبات الوزن مع مونجارو؟ يصل ثبات الوزن خلال 24–36 أسبوع، حسب فئة الوزن: •زيادة وزن: 24 أسبوع •سمنة أولى: 26 أسبوع •سمنة ثانية وثالثة: 36 أسبوع ثبات الوزن يتأخر عند: ✅ الأصغر سنًا ✅ النساء ✅ من يستخدمون جرعات عالية (10-15mg) https://t.co/UgHU4WIMs7 https://t.co/31795BheBq
Time to weight plateau with tirzepatide treatment in the SURMOUNT‐1 and SURMOUNT‐4 clinical trials - Wiley Online Library https://t.co/mZ2TpAyeIC
@bioinvestor24 Source: https://t.co/zVH9WSqdL5
RT @davearterburn: Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials https://t.co/ve62W3z9…
Participants in the SURMOUNT-1 and SURMOUNT-4 trials reached a weight plateau, where weight loss stabilizes, by week 72. Higher doses, younger age, and female sex were associated with longer times to plateau, providing…
This video discusses how long it takes for weight loss to stabilize during tirzepatide treatment, based on the SURMOUNT trials, highlighting factors like dosage, age, and gender that influence when weight plateau occurs.
This video discusses the time it takes for individuals to reach a weight plateau during tirzepatide treatment, based on the SURMOUNT trials. Factors such as dose, age, and sex significantly influence when weight…
@bioinvestor24 Source: https://t.co/zVH9WSqdL5
@EliLillyandCo For example, this analysis of SURMOUNT-1 and -4 found certain demographics had longer periods of weight loss than others. Or might the disparity have been due to a shift in male/female ratios? https://t.co/zVH9WSqdL5 https://t.co/M5LuRjjROZ
متى يوصل الجسم لثبات الوزن مع مونجارو؟ يصل ثبات الوزن خلال 24–36 أسبوع، حسب فئة الوزن: •زيادة وزن: 24 أسبوع •سمنة أولى: 26 أسبوع •سمنة ثانية وثالثة: 36 أسبوع ثبات الوزن يتأخر عند: ✅ الأصغر سنًا ✅ النساء ✅ من يستخدمون جرعات عالية (10-15mg) https://t.co/UgHU4WIMs7 https://t.co/31795BheBq
【備忘】 Clin Obes誌に、RCTデータを用いたセマグルチドによる減量作用持続期間解析。 開始後72週後までは減量が持続。「若年」「女性」では減量持続期間が延長。 https://t.co/sHUmvZ3EFS Jan 12 （ 「この体重でOK」まで下がったらどうすれば？ ）
Time to weight plateau with tirzepatide treatment in the SURMOUNT‐1 and SURMOUNT‐4 clinical trials - Wiley Online Library https://t.co/mZ2TpAyeIC
RT @davearterburn: Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials https://t.co/ve62W3z9…
RT @davearterburn: Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials https://t.co/ve62W3z9…
RT @davearterburn: Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials https://t.co/ve62W3z9…
Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials https://t.co/ve62W3z9jm
Check it out here: https://onlinelibrary.wiley.com/doi/10.1111/cob. 12734 A huge thank you to the **COMMP Research Team** for your hard work and dedication.
2025;15(3):e12734. doi:10.1111/cob.12734 Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in ...
https://doi.org/10.1111/j.1360-0443.2011.03581.x. acterizes heavy cannabis ... 12734. procedural learning? Memory 14 (5), 521e539. https://doi.org/10 ...
10.1111/cpr.12514. Zhou, Y., T. Wang, Q. Meng, and S. Zhai. 2016 ... C. O. B. Rosa, and S. Franceschini. 2019. “Nutritional screening tools used and
Child & Family Social Work, 25(S1), 135–148. https:/doi.org/10.1111/cfs.12734 ... Cobb, C. T. (2012). Restructuring and aligning early education ...
%R 10.1111/jopr.13821 %M WOS:001143116900001 %Z Alfaraj, Amal Lin, Wei-Shao ... Role of corn cob waste biosilica on mechanical, wear, thermal conductivity, and
Environ Sci Technol 46:12726–12734. [Link] org/10.1021/es302302g ... cob biochar application on a tropical sandy loam. J Soil Sediment 20(4):1960 ...
10.1111/ppl.12836. Barron-Gafford GA , et al 2017 Impacts of hydraulic ... Environmental Science and Technology 46, 12726–12734. Meyer S , Glaser B ...
http:// onlinelibrary.wiley.com/doi/10.1111/j.1863-2378 .2009.01267.x/pdf 6. ... Viral Immunol 2010; 23: 12734. 51. Wang G, Song T, Yu Y, et al. Immune ...
... 10.1111/wrr. 12296. Epub 2015 Jun 19. 14. Hight AE, Kalluri R. A biophysical ... 12734. vi. Epub 2017 Nov 22. en yk. 22. Zivkovic VD Stankovic ...
https://onlinelibrary.wiley.com/doi/10.1111/cob.12734. Based on the Surmount trials with a focus on Surmount 4. Which also discussed this 18 ...
... not a dose bound. https://onlinelibrary.wiley.com/doi/10.1111/cob.12734. In short 20% loss is the average - some lose more and some less.
... a read about why low slow plateau is a terrible idea. https://onlinelibrary.wiley.com/doi/10.1111/cob.12734 · Smooth-Owl-5354. • 6d ago • ...
https://onlinelibrary.wiley.com/doi/10.1111/cob.12734. Kevin Hall is a lead research who has extensively studied diets and glp1s and his ...
Te doy la información de este estudio DOI: 10.1111/cob.12734 #tirzepatide #glp1 #obesidad · sonido original - Dr.Dam. 1795Me gusta. 74 ...
Te doy la información de este estudio DOI: 10.1111/cob.12734 #tirzepatide #glp1 #obesidad · sonido original - Dr.Dam. 1798Me gusta. 74 ...
Te doy la información de este estudio DOI: 10.1111/cob.12734 #tirzepatide #glp1 #obesidad · sonido original - Dr.Dam. 1799Me gusta. 74 ...
... majority of participants. This is the full article: https://onlinelibrary.wiley.com/doi/10.1111/cob.12734 · OceanBlue011729. OP • 1mo ago.
https://onlinelibrary.wiley.com/doi/10.1111/cob.12734. The link is information about the plateau happening as you mentioned. CuteProfile8576. • ...
... 10.1111/cob.12734. Unfortunately for me, my provider wasn't that engaged is dose escalation. I was their first patient on Zepbound as they ...
Te doy la información de este estudio DOI: 10.1111/cob.12734 #tirzepatide #glp1 #obesidad · sonido original - Dr.Dam. 1800Me gusta. 74 ...
Te doy la información de este estudio DOI: 10.1111/cob.12734 #tirzepatide #glp1 #obesidad · sonido original - Dr.Dam | GLP-1. 1451Me gusta. 63 ...
... 10.1111/cob.12734. Finally, there seems to be a tension between relying on the authority of science while also referencing anonymous ...
Te doy la información de este estudio DOI: 10.1111/cob.12734 #tirzepatide #glp1 #obesidad · sonido original - Dr.Dam. 1741Me gusta. 72 ...
Clin Obes. 2025;15(3):e12734. doi:10.1111/cob.12734. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for ...
Te doy la información de este estudio DOI: 10.1111/cob.12734 #tirzepatide #glp1 #obesidad · sonido original - Dr.Dam | GLP-1. 1393Me gusta. 63 ...
Te doy la información de este estudio DOI: 10.1111/cob.12734 #tirzepatide #glp1 #obesidad · sonido original - Dr.Dam | GLP-1. 1458Me gusta. 63 ...
https://onlinelibrary.wiley.com/doi/10.1111/cob.12734 · https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24027. I'm nearly one year in ...
... 10.1111/cob.12734. #tirzepatide #glp1 #obesidad. pérdida de peso estudio, sobrepeso y obesidad diferencia, obesidad vs sobrepeso datos ...
Te doy la información de este estudio DOI: 10.1111/cob.12734 #tirzepatide #glp1 #obesidad · sonido original - Dr.Dam. 1793Me gusta. 74 ...
Te doy la información de este estudio DOI: 10.1111/cob.12734 #tirzepatide #glp1 #obesidad · sonido original - Dr.Dam. 1717Likes. 72Comments. 205 ...
Te doy la información de este estudio DOI: 10.1111/cob.12734 #tirzepatide #glp1 #obesidad · sonido original - Dr.Dam | GLP-1. 1202Me gusta. 61 ...
... según el estudio DOI: 10.1111/cob.12734. #tirzepatide #glp1 #obesidad”.
Te doy la información de este estudio DOI: 10.1111/cob.12734 #tirzepatide #glp1 #obesidad · sonido original - Dr.Dam | GLP-1. 578Me gusta. 30 ...
Te doy la información de este estudio DOI: 10.1111/cob.12734 #tirzepatide #glp1 #obesidad · sonido original - Dr.Dam | GLP-1. 1398Me gusta. 63 ...
... 10.1111/cob.12734 . I started at a BMI of 48 so Class III Obesity and I am older so when the scale didn't move down, I thought maybe I am ...
Te doy la información de este estudio DOI: 10.1111/cob.12734 #tirzepatide #glp1 #obesidad · sonido original - Dr.Dam | GLP-1. 1313Me gusta. 63 ...
... 10.1111/cob.12734 parlano del tempo per raggiungere il plateau. Nel secondo articolo linkato: "Dosi più alte di tirzepatide (10/15 mg), età ...
SURMOUNT-1 by starting BMI. (All doses are mixed together in this - 5/10/15mg.) https://onlinelibrary.wiley.com/doi/full/10.1111/cob.12734 · Ok- ...
... /doi/full/10.1111/cob.12734. Edit: This is where I pulled the average starting BMI # from for those with BMIs 40 or greater. ShiftyMcHax. • ...
... -1 by starting BMI category. (They also look at SURMOUNT-4.) https://onlinelibrary.wiley.com/doi/full/10.1111/cob.12734 · BoundToZepIt. • 5mo ...
It matters how much time has past. https://onlinelibrary.wiley.com/doi/10.1111/cob.12734 · https://onlinelibrary.wiley.com/doi/epdf/10.1002 ...
https://onlinelibrary.wiley.com/doi/10.1111/cob.12734. Look at the graphs. All doses plateaued at 18 months. Its not hard to visually see ...
... 10.1111/cob.12734. Depending on different factors you will reach a plateau between 24 and 72 weeks. GLP-1 and GIP are just two of eight ...
Te doy la información de este estudio DOI: 10.1111/cob.12734 #tirzepatide #glp1 #obesidad · sonido original - Dr.Dam | GLP-1. 1393Me gusta. 63 ...
Te doy la información de este estudio DOI: 10.1111/cob.12734 #tirzepatide #glp1 #obesidad · sonido original - Dr.Dam | GLP-1. 900Me gusta. 43 ...
... 10.1111/cob.12734. #tirzepatide #glp1 #obesidad. Keywords: pérdida de peso estudio, sobrepeso y obesidad diferencia, obesidad vs sobrepeso ...
... 10.1111/cob.12734 · https://www.nejm.org/doi/full/10.1056/NEJMoa2410819. I'll keep looking for the others. A few were articles about studies.
... 10.1111/cob.12734 --which used the same definition of "plateau." This analysis of SURMOUNT-1 and 5 data found that (1) people with more ...
... 10.1111/cob.12734. Apa yang kajian ni tambah? Dalam analisis penerokaan ni, majoriti peserta yang dirawat dengan tirzepatide capai plateau ...
... 10.1111/cob.12734. What does this study add? In this exploratory analysis, the majority of participants treated with tirzepatide reached a ...
... 10.1111/cob.12734. What does this study add? In this exploratory analysis, the majority of participants treated with tirzepatide reached a ...
... numbers. Here's the study this came from: https://onlinelibrary.wiley.com/doi/full/10.1111/cob.12734 · Content_Display844. OP • 10mo ago.
... 10.1111/cob.12734#. I say this a lot, buy this is why (and the study above supports) monthly titration to max tolerated dose (as per ELs ...
This study came out in January 2025. https://onlinelibrary.wiley.com/doi/full/10.1111/cob.12734. 1.Time To Weight-loss Plateau (TTWP) by BMI ...
... 10.1111/cob.12734 I had read an earlier article as well. It's not just my analysis but others analysis as well plus there is a comment from ...
... 10.1111/cob.12734. Community Info Section. r/tirzepatidecompound. Join. tirzepatidecompound. Welcome to Reddit's largest Tirzepatide Community ...
Check it out here: https://onlinelibrary.wiley.com/doi/10.1111/cob. 12734 A huge thank you to the **COMMP Research Team** for your hard ...
¿Quién pierde más peso: sobrepeso u obesidad? Descubre qué grupo pierde mayor cantidad de peso según el estudio DOI: 10.1111/cob.12734.
A non-linear Cobb–Douglas If warranted, a suitable informal sector ... 10.1111/agec.12734. India: Exclusion, Policy and Mechanisms,” “Small ...
Te doy la información de este estudio DOI: 10.1111/cob.12734 #tirzepatide #glp1 #obesidad · sonido original - Dr.Dam | GLP-1. 1330Me gusta. 63 ...
Te doy la información de este estudio DOI: 10.1111/cob.12734 #tirzepatide #glp1 #obesidad · sonido original - Dr.Dam. 1799Me gusta. 74 ...
We are really trying to figure out some options for the inside cobb which is turning into a cement job. ... 10.1111/sed.12734](https://l. facebook ...
DM
宇T
ا
JC
JN
JM
MM
YL